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ABSTRACT: Advanced chronic liver disease (aCLD) represents a major public health concern. aCLD is more 
prevalent and severe in the elderly, carrying a higher risk of decompensation. We aimed at understanding how 
aging may impact on the pathophysiology of aCLD in aged rats and humans and secondly, at evaluating  
simvastatin as a therapeutic option in aged animals. aCLD was induced in young (1 month) and old (16 months ) 
rats. A subgroup of aCLD-old animals received simvastatin (5 mg/kg) or vehicle (PBS) for 15 days. Hepatic and 
systemic hemodynamic, liver cells phenotype and hepatic fibrosis were evaluated. Additionally, the gene 
expression signature of cirrhosis was evaluated in a cohort of young and aged cirrhotic patients. Aged animals  
developed a more severe form of aCLD. Portal hypertension and liver fibrosis were exacerbated as a consequence 
of profound deregulations in the phenotype of the main hepatic cells: hepatocytes presented more extensive cell -
death and poorer function, LSEC were further capillarized, HSC over-activated and macrophage infiltration was  
significantly increased. The gene expression signature of cirrhosis significantly differed comparing young and 
aged patients, indicating alterations in sinusoidal-protective pathways and confirming the pre-clinical  
observations. Simvastatin administration for 15-day to aged cirrhotic rats improved the hepatic sinusoidal milieu, 
leading to significant amelioration in portal hypertension. This study provides evidence that aCLD pathobiology 
is different in aged individuals. As the median age of patients with aCLD is increasing, we propose a real-life pre-
clinical model to develop more reliable therapeutic strategies. Simvastatin effects in this model further 
demonstrate its translational potential. 
Key words: Cirrhosis, portal hypertension, hepatic sinusoid, elderly, liver microcirculation 
 
 
 
The socioeconomic and medical care improvement during 
the last decades has led to a relevant increase in the elderly 
population around the world. This growth of older 
population will continue to outpace that of younger 
population over the next years [1]. Aging is associated 
with a physiological decline in most organ functions, 
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including the liver [2]. Indeed, we have recently described 
the changes occurring in the liver sinusoidal cells during 
healthy aging, demonstrating that aging is accompanied 
by an accumulation of slight, but significant, 
modifications in the hepatic sinusoid that could turn into 
vulnerability in front of chronic or acute liver damage [3]. 
Advanced chronic liver disease (aCLD) represents a 
serious and costly problem for our society. Approximately 
844 million people suffer from a chronic liver condition 
worldwide, making it comparable to other major public 
health problems related to chronic diseases such as 
cardiovascular diseases [4, 5]. The incidence of aCLD 
increases dramatically with age, and is accompanied by 
worse prognosis [6], consequently aging has been defined 
as a major risk factor for the development of chronic liver 
conditions [7, 8]. Importantly, and despite the impact of 
aging on human aCLD, most of the pre-clinical studies 
aimed at understanding liver disease pathophysiology 
have been developed in young animals, with few 
exceptions [9–11]. 
Statins have been proposed for the treatment of 
aCLD. Indeed, pre-clinical studies suggested sinusoidal-
protective properties [12–16], which may explain the 
benefits of statins on portal hypertension, survival and 
hepatocellular carcinoma development observed in 
clinical and epidemiological studies [17–19]. 
Nevertheless, all published pre-clinical studies were made 
in young animals while clinical studies included patients  
with an advanced median age. 
The present study aimed at understanding how aging 
may impact on the pathobiology of aCLD, specially 
focusing on the hepatic microcirculatory dysfunction, 
fibrosis and portal hypertension. We hypothesized that the 
cumulative mild changes observed in the sinusoidal 
milieu of healthy aged livers may have relevant 
consequences during chronic liver injury. 
Secondary aims included the evaluation of 
simvastatin as a therapeutic option in a pre-clinical rat 
model of aged cirrhosis, and to elucidate the mechanisms 
responsible for the possible beneficial effect of the 
treatment.  
 
MATERIALS AND METHODS 
 
Additional materials and methods are included in the 
online supplementary information. 
Induction of cirrhosis & simvastatin treatment 
 
Advanced chronic liver disease was induced in male 
Wistar rats 1-month old (young group; aCLD-young) and 
16-month old (aged group; aCLD-old) through chronic 
exposure to CCl4 and phenobarbital [16, 20]. 
After approximately 14 weeks, once the animals  
developed ascites, CCl4 and phenobarbital administration 
was discontinued. No differences in the hepatotoxicants 
administration period to achieve aCLD were observed 
comparing groups. 5 days after detection of ascites, 
aCLD-young and aCLD-old animals (n=7 per group) 
were exhaustively characterized to accomplish the first 
objective of the study. An additional group of aCLD-old 
animals (n=20) were distributed randomly to investigate 
the effects of simvastatin on portal hypertension, 
microcirculatory dysfunction and fibrosis in the aged 
cirrhotic model. Simvastatin (5 mg/kg) or its vehicle 
(PBS) was administered daily by gavage for 15 days. 
Hemodynamic analysis and subsequent sample 
processing were performed 1 hour after the last 
administration. Simvastatin or its vehicle was prepared by 
a third person, and therefore, the investigators 
administering the drug and performing the experiments  
were not aware of the treatment received by the rats. This 
blinding was maintained until the final analysis of results.  
Animals were kept in environmentally controlled animal 
facilities. All procedures were approved by the laboratory 
animal care and use committee of the University of 
Barcelona and were conducted in accordance with the 
European Community guidelines for the protection of 
animals used for experimental and other scientific  
purposes (EEC Directive 86/609) 
In vivo haemodynamic measurements 
Mean arterial pressure (MAP), portal pressure (PP) and 
portal blood flow (PBF) were measured in old and young 
rats using micro-catheters and transit-time flow probes 
[14]. Hepatic vascular resistance (HVR) was calculated as 
PP/PBF. 
Liver endothelial function 
 
After in vivo hemodynamic measurements, livers were 
quickly isolated and perfused. Liver endothelial function 
was determined as response to incremental doses of the 
endothelium-vasodilator acetylcholine [21]. 
 
Hepatic cells isolation 
 
Hepatocytes, Kupffer cells (KC), Liver Sinusoidal 
Endothelial Cells (LSEC), and Hepatic Stellate Cells  
(HSC) were isolated using well-established protocols 
[22]. Only highly pure and viable cells were used. 
 
Electron microscopy 
 
Liver sinusoidal ultrastructure was characterized using 
electron microscopy as previously described [3, 23]. 
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Histological analysis 
 
Liver samples were fixed in 10% formalin, embedded in 
paraffin, sectioned, and slides were stained with 
hematoxylin and eosin (H&E) to analyze the hepatic  
parenchyma, with Sirius Red for liver fibrosis evaluation, 
with Oil red-O for lipid quantification or with 
corresponding antibodies for protein 
immunohistochemistry (IHC) or immunofluorescence 
(IF). 
 
 
 
 
Table 1. Biometric, biochemical and hemodynamic characteristics in aCLD-young and aCLD-old rats.  
 
  aCLD-young 
4 m.o. 
aCLD-old 
20 m.o. 
% change p-value  
Body weight (g) 371 ± 16 701 ± 35 +88 <0.001 
Liver (g) 10.7 ± 0.6 17.9 ± 0.9 +67 <0.001 
Liver-body weight ratio (%) 2.88 ± 0.13 2.57 ± 0.14 -11 0.09 
AST (U/L) 189 ± 11 304 ± 47 +61 0.03 
ALT (U/L) 82 ± 8 97 ± 8 +20 0.17 
Bilirubin (mg/dL) 0.51 ± 0.24 0.51 ± 0.12 0 >0.20 
Bile production (µL/min*g) 30 ± 8 18 ± 3 -40 0.16 
Albumin (mg/dL) 26 ± 1 20 ± 2 -24 0.01 
Plasma cholesterol (mg/dL) 75 ± 5 106 ± 11 +41 0.01 
Plasma LDL cholesterol (mg/dL) 45 ± 4 75 ± 8 +66 0.007 
Plasma HDL cholesterol (mg/dL) 20 ± 2 13 ± 2 -33 0.03 
Plasma triglycerides (mg/dL) 41 ± 8 84 ± 13 +107 0.01 
Plasma FFA (mg/dL) 623 ± 67 504 ± 70 -19 >0.20 
Oil red O-staining (%) 0.47 ± 0.14 1.83 ± 0.32 +289 0.04 
MDA (nmol/mg protein) 2.68 ± 0.68 2.36 ± 0.28 -12 >0.20 
LPS (EU/mL) 1.13 ± 0.19 2.00 ± 0.13 +77 0.002 
PP (mmHg) 14.3 ± 0.3 16.9 ± 1.2 +18 0.03 
PBF (mL/min*g) 1.21 ± 0.12 1.59 ± 0.23 +31 0.12 
HVR (mmHg*min/mL*g) 12.7 ± 1.4 12.5 ± 2.3 -2 >0.20 
Ex vivo HVR (mmHg*min/mL*g) 0.23 ± 0.03 0.41 ± 0.04 +78 0.002 
MAP (mmHg) 91 ± 6  103 ± 7 +13 >0.20 
HR (bpm) 340 ± 15 338 ± 16 -0.5 >0.20 
 
Data expressed as mean ± S.E.M. (n = 7 each group). 
AST: aspartate transaminase; ALT: alanine transaminase; LDL: low density lipoprotein; HDL: high density lipoprotein; FFA: free fatty acids; 
MDA: malondialdehyde; LPS: lipopolysaccharide; EU: endotoxin units; PP: portal pressure; PBF: portal blood flow; HVR: hepatic vascular 
resistance; MAP: mean arterial pressure; HR: heart rate. 
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Figure 1. Hepatocyte phenotype markers in 4 months-young and 20 months-old rats with aCLD. (A) Representative 
transmission electron microscopy images and corresponding quantification of numbers of sinusoids (S), lack of microvilli (M), big 
space of Disse (D), peliosis(P), basal lamina deposition and number of necrotic hepatocytes (H) in liver tissue from 4 months-young 
and 20 months-old rats with aCLD. (B) HNF4α, Oct1, Mrp2 and Mrp3 mRNA expression in livers described in A. n=3 (A) and (B) 
n=7 per group. Results represent mean ± S.E.M. All images: 3000X, scale bar=20μm. 
 
Nitric oxide and superoxide determinations 
 
Levels of cGMP, marker of nitric oxide bioavailability,  
were analyzed in liver homogenates using an enzyme 
immunoassay following manufacturer instructions 
(Cayman Chemical Co., Ann Arbor, MI) [24]. In situ 
mitochondrial or total superoxide levels in hepatic tissue 
or in cells were assessed with the mitochondrial oxidative 
fluorescent dye MitoSOX (MitoSOX 5µM; Molecular  
Probes Inc., Eugene, OR) or with the total oxidative 
fluorescent dye dihydroethidium (DHE 10µM; Molecular  
Probes Inc., Eugene, OR) respectively as described [25, 
26]. Fluorescence images were obtained with a 
fluorescence microscope (Olympus BX51, Tokyo, Japan), 
and quantitative analysis of at least 20 images per 
condition containing equivalent number of cells was 
performed with Image J 1.44m software.  
Human liver mRNA analysis 
 
Fractions of liver biopsy specimens obtained by 
transjugular route, and primarily processed for clinical 
pathology, were stored in diethyl pyrocarbonate (DEPC) 
solution for mRNA isolation using the RNeasy kit 
(Qiagen). 250 ng of highly pure and preserved RNA were 
deeply analyzed using the Illumina Whole Genome-
DASL assay, which quantifies approximately 24,000 
transcripts. The microarray data were deposited and 
stored in GEO (GSE77627). 
Illumina were processed using lumi package quantile 
normalisation [27]. Coefficient for age, derived from a 
linear model using probe set expression versus age and 
gender adjusted [28], was employed as a metric score to 
evaluate the influence of age in the gene expression from 
cirrhotic liver tissue. We performed pre-ranked gene set 
enrichment analysis (GSEA) using the canonical 
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pathways MSigDB collection signatures [29]. 
Ethics Committee of the Barcelona Hospital Clinic  
approved the experimental protocol (HCB/2011/6814).  
Experimental groups were defined considering patients’ 
age: young (n=7, mean age 42 ± 5 years old, range 33-48), 
old (n=7, mean age 62 ± 4, range 58-70).  
 
 
 
Statistical Analysis 
 
Statistical analysis was performed with the SPSS for 
Windows statistical package (IBM, Armonk, New York,  
USA). All results are expressed as mean ± standard error 
of the mean (S.E.M.). Comparisons between groups were 
performed with Student’s t test. Differences were 
considered significant at a p value <0.05. 
 
 
 
 
 
 
 
 
 
 
Figure 2. LSEC phenotype markers in 
aged rats with aCLD. The following 
markers of sinusoidal endothelial 
phenotype were analysed in liver tissue 
from 4 months-young and 20 months-
aged rats with aCLD. (A) mRNA 
expression of KLF2 and CD32b. (B) 
Representative images of CD32b 
immunehistochemistry and 
corresponding quantification. (C) 
Representative images of eNOS 
immunohistochemistry and 
corresponding quantification. (D) 
Representative images of vWF 
immunohistochemistry and 
corresponding quantification. (E) mRNA 
expression of HGF, Wnt2, Hamp and 
Axin2. (F) Representative scanning 
electron microscopy images & 
quantification of porosity, fenestration 
frequency and fenestration diameter. n=7 
(A-E) and n=3 (F) per group. Results 
represent mean ± S.E.M. Images from B-
D: 400X, scale bar=50μm. Images from 
F: 15000X, scale bar=1μm. 
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Figure 3. Aging increases fibrotic 
deposition, HSC activation and 
macrophages infiltration. Fibrotic 
content, HSC phenotype and 
macrophage infiltration and phenotype 
were evaluated in young and aged rats 
with aCLD. (A) Representative images  
of fibrotic content measured as 
positive area for Sirius Red with their 
corresponding quantifications. (B) 
Representative western blot of 
Collagen I normalized to GAPDH. (C) 
Representative western blot of -SMA 
normalized to GAPDH. (D) 
Representative western blots of 
moesin and p-moesin and 
corresponding quantification. (E) Left,  
representative images of CD68 
immunofluorescence in liver tissue 
and corresponding quantification. 
Right, representative images of CD163 
immunohistochemistry in liver tissue 
and its quantification. (F) Expression 
of TNF-α, iNOS, and IL-6 as pro-
inflammatory markers (left) and Mrc1, 
Arg1 and IL-10 as anti-inflammatory 
markers (right) in liver tissue from 
young and old rats with aCLD. n=7 per 
group. Results represent mean ± 
S.E.M. All images: 400X, scale 
bar=50μm.  
 
RESULTS 
 
Aged rats with aCLD: baseline biometric and 
biochemical characteristics. 
 
As shown in Table 1, old rats with aCLD showed an 
increase in body and liver weight compared to young 
aCLD animals; however, liver/body-weight ratio was 
moderately diminished. Evaluation of hepatic function 
suggested a more severe deterioration in the aging group, 
shown by lower plasma albumin levels and bile 
production and higher serum transaminases. 
Evaluation of plasma lipids revealed higher total 
cholesterol, LDL-cholesterol, HDL-cholesterol and 
triglycerides, without significant changes in free fatty 
acids. Moreover, old rats with aCLD had higher hepatic 
lipid accumulation as compared to young rats analyzed by 
oil red-o-staining. 
Interestingly, plasma levels of LPS were significantly 
higher in aged animals with aCLD, suggesting increased 
bacterial translocation in this group. 
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Figure 4. Aged-related changes in the gene signature of cirrhotic human liver. Gene expression 
analysis in cirrhotic young and old human livers. (A) Left, fold enrichments (log2) are plotted in a heatmap 
using red colour for transcripts that are increased or using green colour for transcripts that are decreased 
in old cirrhotic humans. Right, pathway enrichment analysis results for genes upregulated (red) and 
downregulated (green) are summarized. (B) Representative gene sets upregulated (red) or downregulated 
(green) related to microcirculatory function in old cirrhotic humans, full description of top ten gene sets 
can be found in supplementary materials. FDR < 10%, n=7 per group. Clinical characteristics of donors 
are described in Supplementary table 1. 
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Figure 5. Effects of 
simvastatin on hepatocytes 
and microcirculatory 
function. (A) HNF4α, Oct1, 
Mrp2 and Mrp3 mRNA 
expression in livers from aged 
rats with aCLD treated with 
simvastatin or vehicle. (B) 
Cytochrome P4503A4 activity 
in hepatocytes isolated from 
livers described in A. (C) 
Representative transmission 
electron microscopy images  
and corresponding 
quantification of numbers of 
sinusoids (S), lack of microvilli 
(M), big space of Disse (D), 
peliosis and number of necrotic 
hepatocytes (H). (D) 
Microvascular function 
evaluation in livers from aged 
rats with aCLD treated with 
simvastatin or vehicle. (E)  
Representative images of vWF 
immunohistochemistry and 
corresponding quantification 
from livers described in A. (F) 
Representative scanning 
electron microscopy images & 
quantification of porosity, 
fenestration frequency and 
fenestration diameter. n=10 
(A-B, D-E), n=5 (B) and n=3 
(C and F) per group. Results 
represent mean ± S.E.M. 
Images from C: 3000X, scale 
bar=20μm. Images from E: 
400X, scale bar=50μm. Images  
from F: 15000X, scale 
bar=1μm. 
 
Portal hypertension is aggravated in aged rats with 
aCLD 
 
Old animals with aCLD had significantly higher portal 
pressure (+18%) in comparison to young cirrhotic animals 
(Table 1), which was the consequence of further increases 
in both portal blood inflow and hepatic vascular 
resistance. Systemic hemodynamic parameters showed no 
differences between groups.  
Analysis of ex vivo hepatic vasodilatory capacity in 
response to incremental concentrations of acetylcholine 
revealed no differences between age groups (data not 
shown). 
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Aged rats with aCLD present deterioration in 
hepatocyte phenotype 
 
Ultrastructural analysis of liver architecture using 
transmission electron microscopy revealed that aged 
cirrhotic rats exhibit greater liver injury when compared 
to young. Indeed, and as shown in Figure 1A, old livers 
with aCLD presented decreased number of sinusoids, loss 
of hepatocyte microvilli, greater presence of erythrocytes 
inside the space of Disse (peliosis), further deposition of 
basal lamina in the sinusoid, and a significant increase in 
the percentage of necrotic hepatocytes. Further analysis of 
hepatocyte phenotype markers in liver tissue confirmed a 
marked deregulation in aging (Fig 1B). 
 
The sinusoidal endothelium of aged rats with aCLD is 
further capillarized 
 
As shown in Figure 2, the expression of a variety of 
vasoprotective, vasodilatory and angiocrine molecules,  
including the transcription factor KLF2, the LSEC-
specific marker CD32b, and the anti-inflammatory and 
vasodilatory protein eNOS, were significantly 
deregulated in old cirrhotic livers in comparison to young. 
Additional LSEC analysis using scanning electron 
microscopy revealed a reduction in fenestrae porosity and 
frequency, altogether suggesting that aged cirrhotic rats 
undergo significantly greater sinusoidal capillarization. 
 
Aged cirrhotic animals exhibit exacerbated fibrosis 
and over-activation of HSC and macrophages  
 
Analysis of extracellular matrix deposition in aged 
cirrhotic livers evidenced a significant increment in 
hepatic fibrosis, as demonstrated by increased Sirius Red 
staining (Fig. 3A) and collagen I protein expression (Fig. 
3B). According with this result, HSC phenotype markers 
α-SMA and phosphorylated moesin were overexpressed 
in aged cirrhotic liver tissue (Fig. 3C & D), with no 
differences in desmin expression (data not shown), thus 
suggesting over-activation of this hepatic cell type. 
Finally, characterization of the hepatic macrophage 
phenotype revealed increased infiltration of CD68+ cells  
(Fig. 3E) with no differences in CD163+ cells (Fig. 3E), 
and significant differences in the mRNA expression of 
different cytokines including TNFα, Mrc1 and Arg1 (Fig. 
3F). 
 
Livers from old patients display significant variations 
in the gene expression signature of cirrhosis 
 
Supplementary table 1 shows the clinical and biochemical 
parameters of patients with aCLD included in the 
microarray analysis. Interestingly, older cirrhotic patients 
exhibited higher hepatic venous pressure gradient 
(HVPG) than young, with no differences in biochemical 
or clinical determinations except for gender. Possible 
gender influence in the analysis of gene expression was 
prevented as described in the methods section. 
Analysis of gene expression in liver tissue identified 
382 genes differentially expressed comparing young and 
aged cirrhotic patients (Fig. 4A). 204 genes were over-
expressed while 178 genes were downregulated in aging. 
A more comprehensive characterization of the aged 
cirrhotic liver gene signature was performed using 
pathway enrichment analysis (PEA). PEA for upregulated 
genes showed 4663 gene sets significantly enriched at a 
false discovery rate (FDR)<25%, while 52 were 
significantly enriched at FDR<10%. Supplementary table 
2 shows the top ten significantly upregulated pathways. 
Focusing on the top upregulated pathways related to 
vascular pathobiology, these included: negative 
regulation of vascular development, response to retinoic  
acid, collagens and regulation of macrophage 
differentiation (Supplementary table 3 and Fig. 4B). 
PEA for downregulated pathways showed 919 gene 
sets significantly enriched at FDR<25%, being 4 gene sets 
significantly enriched at FDR<10%. Top ten significantly 
downregulated pathways are detailed in Supplementary 
table 4, and included olfactory signalling pathway and 
neuron fate specification, among others.  
Aged cirrhotic rats treated with simvastatin: 
biometric and biochemical characteristics 
 
In comparison to vehicle, simvastatin-treated rats 
presented no differences in body weight, and a slight non-
significant increase in liver mass (Table 2). Biochemic al 
analysis showed improvements in bilirubin and albumin,  
which together with increased bile production and no 
modification in creatine kinase from muscle, suggested a 
global improvement in hepatic injury without toxic 
effects. No differences in plasma lipid spectrum were 
observed comparing both groups. 
 
Simvastatin improves portal hypertension in aged rats 
with cirrhosis 
 
Aged rats with aCLD treated with simvastatin exhibited a 
significant improvement in PP (-25%), associated with 
slight decreases in PBF and HVR, in comparison with 
vehicle (Table 2). In addition, systemic hemodynamics 
seemed to be ameliorated. 
 
Simvastatin improves the hepatocyte phenotype in 
aged cirrhotic rats 
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Primary hepatocytes from old rats with aCLD treated with 
simvastatin showed a significant improvement in several 
phenotypic markers related with hepatic functionality 
including upregulation in HNF4α, Oct1 and Mrp2 (Fig. 
5A). Additionally, the activity of cytochrome P4503A4 
was slightly higher compared to hepatocytes from 
vehicle-treated rats (Fig. 5B). Further analysis of hepatic  
damage in liver tissue using transmission electron 
microscopy revealed a significant improvement in 
response to simvastatin, including maintenance of 
hepatocyte microvilli, a decrease in the presence of 
enlarged spaces of Disse, and a reduction in peliosis (Fig. 
5C).  
 
 
 
Figure 6. S imvastatin promotes decreased fibrosis deposition and HSC de-activation. (A) Representative images of fibrotic 
content, α-SMA and desmin with their corresponding quantifications. (B) α-SMA and Collagen I protein expression in total liver 
tissue, normalized to GAPDH. (C) Representative western blots of moesin and p-moesin and corresponding quantification. n=10 
(A-C). Results represent mean ± S.E.M. All images 400X, scale bar=50μm. 
 
Simvastatin improves liver endothelial dysfunction in 
aged rats with aCLD 
 
Analysis of the hepatic microcirculatory function using ex 
vivo liver perfusion revealed that old cirrhotic rats treated 
with simvastatin exhibited a significant improvement in 
their endothelium-dependent vasodilatory capacity (Fig. 
5D), which correlated with decreased sinusoidal 
expression of the capillarization marker vWF (Fig. 5E). 
Sinusoidal porosity as well as the number of fenestrae was 
significantly improved in the group of aged cirrhotic rats 
treated with simvastatin in comparison to those receiving  
vehicle (Fig. 5F). In concordance with this finding, the 
hepatic expression of caveolin-1, protein upregulated 
when fenestrae disappear [30], was significantly 
decreased in simvastatin-treated rats (Supplementary Fig. 
1A). LSEC phenotype amelioration after simvastatin 
treatment was further confirmed observing up-regulation 
in the mRNA expression of KLF2, CD32b, Hamp and 
Axin2 (Supplementary Fig. 1B & C), and down-
expression of CD31 (Supplementary Fig. 1D) and ICAM-
1 (Supplementary Fig. 1E & F). In contrast, we did not 
observe differences between groups in the NO-eNOS 
pathway (Supplementary Fig.2). 
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Table 2. Biometric, biochemical and hemodynamic characteristics in aCLD-old rats treated with simvastatin or vehicle. 
 
  Vehicle Simvastatin % change p-value  
Body weight (g) 655 ± 31 681 ± 18 +4 > 0.20 
Liver (g) 16.6 ± 1.0 19.1 ± 1.1 +15 0.15 
Liver-body weight ratio (%) 2.58 ± 0.19 2.81 ± 0.15 +9 > 0.20 
AST (U/L) 188 ± 34 155 ± 28 -18 > 0.20 
ALT (U/L) 61 ± 5 57 ± 6 -7 > 0.20 
CKM (ng/mL) 64 ± 13 47 ± 10 -27 > 0.20 
Bilirubin (mg/dL) 0.23 ± 0.06 0.10 ± 0.00 -57 0.05 
Bile production (µL/min*100g bw) 23.5 ± 7.1 42.0 ± 16.5 +45 0.17 
Albumin (mg/dL) 22.0 ± 1.1 24.2 ± 0.8 +10 0.10 
Plasma cholesterol (mg/dL) 86 ± 5 79 ± 10 -8 > 0.20 
Plasma LDL cholesterol (mg/dL) 64 ± 5 55 ± 7 -14 > 0.20 
Plasma HDL cholesterol (mg/dL) 14.0 ± 1.5 15.6 ± 2.6 +7 > 0.20 
Plasma triglycerides (mg/dL) 38.0 ± 5.1 42.1 ± 7.1 +11 > 0.20 
Oil red O-staining (%) 1.33 ± 0.22 1.64 ± 0.39 +23 > 0.20 
MDA (nmol/mg protein) 2.68 ± 0.74 2.35 ± 0.30 -12 0.15 
LPS (EU/mL) 1.49 ± 0.18 1.62 ± 0.13 +8 > 0.20 
PP (mmHg) 15.9 ± 1.4 11.9 ± 0.8 -25 0.02 
PBF (mL/min*g) 1.28 ± 0.17 1.13 ± 0.16 -12 >0.20 
HVR (mmHg*min/mL*g) 13.9 ± 2.4 12.4 ± 1.5 -11 >0.20 
Ex vivo HVR (mmHg*min/mL*g) 0.39 ± 0.04 0.32 ± 0.03 -18 0.20 
MAP (mmHg) 97 ± 6 110 ± 5 +13 >0.20 
HR (bpm) 332 ± 22 381 ± 25 +15 0.06 
 
Data expressed as mean ± SEM (n = 10 each group). 
AST: aspartate transaminase; ALT: alanine transaminase; CKM: Creatinine kinase from muscle; LDL: low density lipoprotein; HDL: high 
density lipoprotein; MDA: malondialdehyde; LPS: lipopolysaccharide; EU: endotoxin units; PP: portal pressure; PBF: portal blood flow; HVR: 
hepatic vascular resistance; MAP: mean arterial pressure; HR: heart rate. 
Simvastatin decreases liver fibrosis and promotes 
deactivation of HSC  
 
Aged rats with aCLD treated with simvastatin showed 
significantly lower hepatic fibrosis when compared to 
vehicle as demonstrated by significant reductions in Sirius  
Red staining and collagen I (Fig. 6A & B). Expression of 
the activation marker α-SMA decreased in response to 
statin (Fig. 6A & B), while we observed no differences in 
desmin marker indicating no changes in HSC abundance 
(Fig. 6A). HSC contractility was decreased by 
simvastatin, as suggested by reduced expression of p-
moesin (Fig. 6C) and reduced in vitro contractility of 
primary human HSC (Supplementary Fig. 3A). 
Oxidative stress, a well-known pro-fibrogenic 
stimulus, was attenuated both in liver tissue and primary 
HSC isolated from aged cirrhotic rats treated with 
simvastatin (Supplementary Fig. 3B - D). 
Simvastatin ameliorates the pro-inflammatory status of 
aged cirrhotic rat livers 
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As shown in Supplementary Figure 4, CD68+ 
macrophage infiltration was significantly reduced in 
simvastatin-treated rats, with no changes in CD163+ 
positive cells and neutrophil infiltration (data not shown). 
Accordingly, the mRNA expression of several cytokines 
was decreased in simvastatin-treated rats. 
 
DISCUSSION 
 
Due to its high incidence worldwide, advanced chronic 
liver disease (aCLD) has become a major public health 
problem comparable to diabetes [4, 5]. Epidemiological 
data confirm that cirrhosis is more prevalent in the elderly 
[31], it progresses faster in this sub-group of patients [32] 
and importantly, that decompensation is more frequent in 
older patients (14%) compared to younger ones (4%) [33, 
34]. 
In the pre-clinical scenario little is known about the 
impact of aging on liver diseases. Previous work 
suggested higher rate of fibrosis deposition in aged rats 
and attributed this to alterations in the immune response 
[9, 10]. However, this is the first study that evaluates the 
impact of aging on the hepatic sinusoidal milieu in a 
validated pre-clinical model of aCLD, focusing on the 
pathophysiology of the disease and its hemodynamic  
alterations. 
The main finding of the present study is that aged 
animals develop a more severe form of aCLD, which can 
be broadly defined by poorer hepatic function and 
exacerbated portal hypertension, fibrosis and 
inflammation. Indeed, aged rats with cirrhosis exhibited 
serious liver damage reflected by the increase in 
transaminases and the reduction in serum albumin and 
bile production in comparison with young rats with aCLD. 
Interestingly, aging was also accompanied by increases in 
both systemic and hepatic lipid content which can be an 
important source of oxidative stress; a well-known 
detrimental factor in the pathophysiology of portal 
hypertension and aCLD [35]. Hepatocytes experienced 
profound deregulations in their phenotype and more 
extensive cell death, which together with increased 
fibrosis caused greater hepatic architecture deterioration. 
Indeed, increased hepatocyte necrosis could also over-
stimulate HSC activation and therefore further contribute 
to disease exacerbation [36]. Considering the high index 
of cell death observed in the aged group, a caspase 
inhibitor may be an attractive target for the treatment of 
chronic liver diseases [37]. 
At the microcirculatory level, we describe for the first 
time that aged rats with aCLD show a marked aggravation 
in portal hypertension, which could be explained by 
increments in both vascular resistance and liver blood 
inflow. We hypothesized that the deterioration of the 
intrahepatic microcirculatory status is a consequence of 
overall deregulations in the phenotype of the main liver  
cells. 
Although no significant differences in microvascular 
dysfunction were observed between young and aged 
cirrhotic animals, a comprehensive analysis of sinusoidal 
de-differentiation markers revealed alterations in LSEC 
phenotype including a reduction in the nitric oxide 
synthase pathway, depletion of angiocrine mediators and 
importantly, reduced porosity and frequency of fenestrae. 
These observations agree with previous studies reporting 
pseudo-capillarisation of the sinusoidal endothelium 
during healthy aging [3, 38], revealing that these changes 
are much intensified in aged livers affected by chronic 
injury.  
In addition to LSEC, HSC play a key role modulating 
the hepatic vascular resistance in cirrhosis [39]. 
Importantly, we herein describe that old HSC undergo 
significant changes due to chronic liver injury, which 
ultimately lead to expanded deposition of extracellular  
matrix in comparison to young animals. Interestingly,  
previous pre-clinical studies suggested an increment in 
hepatic fibrogenesis in aging [9, 10, 40], however we 
describe such aggravation in a model of decompensated 
cirrhosis that better reflects the clinical observations [32, 
41]. 
The role of inflammation in the progression of CLD 
has been widely described in the past, and recently 
reviewed [42], nevertheless much less is known in the 
context of aging [10, 40]. In our study, and in comparison, 
to young animals, we observe that aged cirrhotic rats 
exhibit further deterioration in the hepatic inflammatory 
phenotype as demonstrated by a significant increase in the 
recruitment of proinflammatory macrophages together 
with a decrease in the expression of pro-resolution 
cytokines in this cellular sub-population. The increase in 
the myeloid cell content in the aged cirrhotic liver may 
derive from the sinusoidal endothelial activation 
described above, and importantly, this could be another 
mechanism contributing to microcirculatory dysfunction 
and global worsening of the disease [43]. 
In addition and aimed at understanding the 
translatability of our pre-clinical discoveries, we 
characterized the hepatic transcriptome in two groups of 
cirrhotic patients of different age. Although the cohort of 
patients included was small, the result of these analyses  
confirmed the alterations observed in the aging rat model: 
endothelial deregulation, HSC over-activation, enhanced 
fibrogenesis and immune cell activation. Altogether, the 
pre-clinical and clinical data obtained in this study suggest 
that the pathophysiology of CLD is much worse, and 
probably involves different molecular mechanisms, when 
comparing aged and young individuals. Future studies, 
out of the scope of the present manuscript, will be required 
to further comprehend the impact of the unique gene 
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expression signature of aged cirrhotic livers in the 
progression and regression of CLD. 
Statins are HMGCoA reductase inhibitors originally 
designed as cholesterol-lowering drugs that over the years 
have been re-discovered for their pleiotropic effects on 
inflammation, fibrosis and endothelial function, among 
others [44]. Different studies have reported the benefits of 
statins in experimental models of young cirrhosis [12–14, 
16] but none has evaluated the effect of this therapy in 
aged aCLD.  
In this study we observed that 2-week administration 
of simvastatin to aged cirrhotic rats significantly improves 
liver microvascular dysfunction and portal hypertension, 
accompanied by slight ameliorations in the systemic 
hemodynamic and in hepatic function. 
Underlying mechanisms explaining the global 
benefits of this vasoprotective compound revealed 
reduced disease severity in all major hepatic cell types. 
Hepatocytes exhibited an improved phenotype as 
suggested by ameliorations in their synthetic capacity, in 
blood tests and in the ultrastructural architecture. 
Importantly, we did not observe signs of toxicity due to 
the treatment, suggesting that previous evidence of 
simvastatin toxic effects [45] may derive from the 
experimental model used to induce CLD (common bile 
duct ligation) and/or be dose dependent. Indeed, in our 
study we selected a dose of  5 mg/day/kg in rats, which is 
equivalent to a dose of 80 mg/day in adult humans 
following Reagan-Shaw et al. dose conversion [46], and 
preferred to generate CLD by chronic CCl4 with no 
obstruction of bile secretion, thus preventing drug 
accumulation. 
As expected, simvastatin improved the phenotype of 
sinusoidal cells. The hepatic endothelium increased the 
expression of functional and angiocrine markers, while 
decreased the expression of capillarisation and 
inflammatory markers. Remarkably, aged cirrhotic 
animals treated with simvastatin for 15 days exhibited 
double number and frequency of fenestrae, which in fact 
may contribute to improve parenchymal function through 
a better diffusion of oxygen, nutrients, and waste 
products. It is important to denote that no previous study 
has demonstrated an improvement in sinusoidal porosity 
in response to statin administration in vivo, just one study 
showed amelioration in the fenestrae of the mesenteric 
endothelium in a rat model of arterial hypertension [47]. 
Although our results support that the hepatic endothelium 
was ameliorated due to the treatment, we could not detect 
differences in the nitric oxide pathway when comparing 
both groups of animals. Considering that we tested the 
effects of 15-day simvastatin, treatment period longer 
than in any previously published study, we cannot 
disregard the possibility that a partial spontaneous 
recovery in the vehicle-treated group may have occurred 
and consequently no differences in certain markers could 
be detected. Likewise, we cannot discard that aged rats 
with cirrhosis may exhibit a poor NO-signaling response 
to statins.  
Importantly, simvastatin treatment promoted a 
marked regression in liver fibrosis, which may be due to 
deactivation of HSC, together with a reduction in 
oxidative stress and inflammation. Additionally, HSC 
phenotype improvement could also contribute to the 
amelioration in hepatic microvascular dysfunction.  Our 
observations are in agreement with previous clinical 
observations in patients with liver disease [44]. 
In conclusion, this study provides evidence that 
aCLD has a much-aggravated pathophysiology in aged 
individuals, and even more importantly, that aging may 
activate different or additional molecular mechanisms 
from those observed in young. Considering the increasing 
age of many patients with aCLD, we propose that using 
closer to real-life models to investigate the 
pathophysiology of aCLD may allow the development of 
more reliable therapeutic strategies. In fact, the 
characterization of simvastatin in this model further 
recommends its applicability at the bedside. 
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